Related Experiment Video
Updated: May 10, 2026

Synthesis and Structure Determination of µ-Conotoxin PIIIA Isomers with Different Disulfide Connectivities
Published on: October 2, 2018
Strategies for the development of conotoxins as new therapeutic leads
Ryan M Brady1, Jonathan B Baell, Raymond S Norton
1Monash Institute of Pharmaceutical Science, Monash University, 381 Royal Parade, Parkville 3052, Australia. ryan.brady@monash.edu
Abstract:
Peptide toxins typically bind to their target ion channels or receptors with high potency and selectivity, making them attractive leads for therapeutic development. In some cases the native peptide as it is found in the venom from which it originates can be used directly, but in many instances it is desirable to truncate and/or stabilize the peptide to improve its therapeutic properties. A complementary strategy is to display the key residues that make up the pharmacophore of the peptide toxin on a non-peptidic scaffold, thereby creating a peptidomimetic. This review exemplifies these approaches with peptide toxins from marine organisms, with a particular focus on conotoxins.
More Related Videos
Related Concept Videos
Drug Discovery: Overview
Bacterial Toxins
Pharmaceutical Poisoning: Treatment Strategies
Production of Antibiotics
Antidotes
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
Preclinical Development: Overview

